文献速递复苏、休克与脓毒症心脑血管急症

依达赛珠单抗逆转达比加群抗凝作用——全队列分析

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
PubMed 文献 · N Engl J Med · 2017-07-11
一句话结论在急诊出血或需紧急操作的达比加群患者中,5 g 静脉依达赛珠单抗4小时内实现中位100%抗凝逆转,快速、持久且安全。

RE-VERSE AD 为多中心、前瞻性、开放标签研究,纳入达比加群抗凝且出现无法控制的出血(A组)或即将接受紧急操作(B组)的患者,给予5 g静脉依达赛珠单抗。主要终点为给药后4小时内基于稀释凝血酶时间或蛇静脉酶凝血时间测得的最大逆转百分比,中位最大逆转率为100%(95%CI 100–100)。A组中位止血时间为2.5小时,B组中位操作启动时间为1.6小时,围术期止血正常者占93.4%。90天血栓事件发生率A组6.3%、B组7.4%,死亡率分别为18.8%和18.9%,未出现严重安全性信号。

要点

  • 达比加群相关无法控制的出血(A组)或需紧急操作(B组)患者,5 g静脉依达赛珠单抗4小时内中位最大逆转率100%(95%CI 100–100)。
  • A组可评估患者中位止血时间2.5小时;A组137例(45.5%)为消化道出血,98例(32.6%)为颅内出血。
  • B组中位操作启动时间1.6小时;围术期止血正常93.4%、轻度异常5.1%、中度异常1.5%。
  • 90天血栓事件A组6.3%、B组7.4%;死亡率A组18.8%、B组18.9%;无严重安全性信号。

适用人群与场景

  • 达比加群抗凝且出现无法控制的出血患者(A组,301例)。
  • 达比加群抗凝且即将接受紧急操作的患者(B组,202例)。

处置流程与药物剂量

  • 给予5 g静脉依达赛珠单抗以逆转达比加群抗凝作用,适用于无法控制的出血或需紧急操作的患者。
  • 主要终点为给药后4小时内基于稀释凝血酶时间或蛇静脉酶凝血时间测得的最大逆转百分比。

研究设计与关键结果

  • 多中心、前瞻性、开放标签研究,共纳入503例:A组301例,B组202例。
  • 中位最大逆转率为100%(95%CI 100–100),基于稀释凝血酶时间或蛇静脉酶凝血时间。
  • A组中137例(45.5%)为消化道出血,98例(32.6%)为颅内出血;可评估患者中位止血时间2.5小时。
  • B组中位操作启动时间1.6小时;围术期止血正常93.4%、轻度异常5.1%、中度异常1.5%。
  • 90天血栓事件A组6.3%、B组7.4%;死亡率A组18.8%、B组18.9%。
  • 未出现严重安全性信号。

证据类型、等级与局限

  • 证据类型:多中心、前瞻性、开放标签研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急诊出血或需紧急操作的达比加群患者中,5 g静脉依达赛珠单抗可快速、持久且安全地逆转抗凝作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.

METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in patients who had uncontrolled bleeding (group A) or were about to undergo an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the diluted thrombin time or ecarin clotting time. Secondary end points included the restoration of hemostasis and safety measures.

RESULTS: A total of 503 patients were enrolled: 301 in group A, and 202 in group B. The median maximum percentage reversal of dabigatran was 100% (95% confidence interval, 100 to 100), on the basis of either the diluted thrombin time or the ecarin clotting time. In group A, 137 patients (45.5%) presented with gastrointestinal bleeding and 98 (32.6%) presented with intracranial hemorrhage; among the patients who could be assessed, the median time to the cessation of bleeding was 2.5 hours. In group B, the median time to the initiation of the intended procedure was 1.6 hours; periprocedural hemostasis was assessed as normal in 93.4% of the patients, mildly abnormal in 5.1%, and moderately abnormal in 1.5%. At 90 days, thrombotic events had occurred in 6.3% of the patients in group A and in 7.4% in group B, and the mortality rate was 18.8% and 18.9%, respectively. There were no serious adverse safety signals.

CONCLUSIONS: In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017. PMID: 28693366. doi:10.1056/NEJMoa1707278

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。